ReviewMedical molecular morphology2010
Androgens in human breast carcinoma.
Review in Medical molecular morphology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 50 citations in OpenAlex.
- Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment.Cancers · 2024Review
- Machine learning-guided synthesis of nanomaterials for breast cancer therapy.Scientific reports · 2024Article
- Clinicopathological Characteristics and Prognosis of Triple-Negative Apocrine Carcinoma: A Case-Control Study.World journal of oncology · 2023Article
- Diverse role of androgen action in human breast cancer.Endocrine oncology (Bristol, England) · 2022Review
- Androgen receptor in breast cancer: The "5W" questions.Frontiers in endocrinology · 2022Review
- Androgen Receptor in Breast Cancer: From Bench to Bedside.Frontiers in endocrinology · 2020Review
- ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens.International journal of molecular sciences · 2018Article
- Review
- Cystic apocrine ductal carcinoma in situ with increased EGFR expression, trisomy 7, and associated focal invasion.Medical molecular morphology · 2016Article
- TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation.Cancer medicine · 2016Article
- Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.Medical molecular morphology · 2016Article
- Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.Cancer science · 2014Article
- Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.BMC cancer · 2012Article
- Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.Breast cancer : basic and clinical research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sex steroids play important roles in the development of human breast carcinoma. Androgen receptor (AR) is expressed in a majority of breast carcinoma tissues. However, the significance of androgen actions remains largely unclear in breast carcinoma, differing from estrogen actions. Therefore, in this review, we summarized recent studies on androgens in breast carcinoma. Concentration of a potent androgen, 5alpha-dihydrotestosterone (DHT), was significantly higher in breast carcinoma tissue than in plasma, and DHT is considered to be locally produced from circulating androstenedione by 17beta-hydroxysteroid dehydrogenase type 5 and 5alpha-reductase. On the other hand, aromatase was recently reported as a negative regulator for intratumoral DHT production by possibly reducing the precursor testosterone. Androgens predominantly show antiproliferative effects in breast carcinoma cells, but association between AR status and the clinical outcome of the patient remains controversial, perhaps partly because AR status does not necessarily reflect androgenic action in breast carcinoma. Recently, molecular apocrine breast carcinoma was identified by microarray analysis. Molecular apocrine carcinoma was characterized by being estrogen receptor (ER) negative and AR positive and by being associated with increased androgen signaling and apocrine features. Therefore, androgenic actions may also be involved in apocrine features in breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.